The standard of treatment for men who have a localized recurrence in lymph nodes (LN) after surgery is intensity modulated radiation therapy (IMRT) as well as with men who have high-risk prostate cancer which includes cancer in both the prostate and seminal vesicles (SV). As with all treatments the use of IMRT comes with many [...]
Sipuleucel-T (Provenge) has shown in clinical trials that it prolongs overall survival (OS) in asymptomatic or minimally symptomatic men with castrate resistant prostate cancer (CRPC). Unlike many other treatments for men with CRPC there are not any reliable biomarkers to show that it is working for any individual. There is also a lack of markers [...]
There are different methods of performing ADT; these methods include continuous or intermittent as well as differences in the actual blockade itself. Understanding the superior schedule as well as the superior combination of drugs can both delay the onset to castrate resistance as well as provide for a longer overall survival (OS). In a research [...]
On March 4, 2014 I wrote a post “Castrate Resistant Prostate Cancer- What to Do Next” (www.advancedprostatecancer.net/?p=4425). The basic theme of the post was about how difficult it is to know how to sequence the new drugs we have to treat advanced prostate cancer (metastatic castrate resistant prostate cancer aka mCRPC). In the post I [...]
Confusion, confusion and more confusion, that is how I would describe the current decision making process for a man with prostate cancer that has become newly castrate resistant. Just a few years ago the decision tree was clear, castrate resistant, immediately on to chemotherapy with docetaxel. Today, in this treatment space, we have a number [...]